We have noticed much confusion among our broad digital health/virtual-first care network about the definitions of conventional, lifestyle, functional and alternative medicine. To add to the confusion, each picks and chooses techniques from the others to incorporate into their approach. For more than a decade, our team has focused on
NIH Report Shows Why The AIID Epidemic is Invisible An NIH research report on autoimmune disease, published May, 2022, explains why, despite affecting more Americans than cancer, autoimmune and immunoinflammatory diseases (AIIDs) remain an invisible epidemic. Autoimmunity is an orphaned research field of patchwork studies of some 80-150 individual diseases.
A May 2022 NIH Report on autoimmune research makes clear why the AIID epidemic remains invisible & silent.
We’ve compiled some incidence, prevalence and growth estimates for selected autoimmune diseases (AIIDs) as a follow up to our previous post. In that post, we surveyed the sorry state of US national autoimmune incidence & prevalence data. Summary: Per the May 2022 NIH Report: Enhancing Autoimmune Research the US has
Since 2010, we have sought autoimmune disease (AIID) incidence and prevalence data. Despite efforts by independent organizations like AARDA/AA, AIR and many single disease groups, we never found total national autoimmune statistics. NIH/CDC statistics bury AIIDs within siloed categories: Arthritis, diabetes, or by medical specialty: rheumatology, neurology, dermatology, endocrine, etc.
We are here republishing our 2014-17 Stanford MedX autoimmune presentations, plus unpublished material from our 2015 Autoimmune Workshop. As we develop our 2023 State of Autoimmunity Report, we’ve been revisiting our previous analyses. For another example, see our 2016-19 patient-centered vision and business opportunities post. In 2015, Bonnie conducted an
Back in 2019, pre-Covid pandemic, we already saw attractive investment & business opportunities to meet the large and growing need in autoimmune and chronic immuno-inflammatory diseases. Despite being as prevalent as cancer and growing faster, these diseases remain invisible: under-recognized, under-researched and under-served. In particular, multiple medical specialty silos within
A continuation of Part 1. One of our B2B thought leadership interviews with digital health entrepreneurs working to improve the care of chronic conditions. We care particularly about chronic immunoinflammatory disorders (CIIDs), e.g., autoimmune and autoinflammatory diseases. This continues our interview with the CEO of Oshi Health, Sam Holliday. Oshi
First 2021 post in our series of B2B thought leadership interviews with visionary digital health entrepreneurs working to improve care of chronic conditions. In keeping with our mission, we particularly care about chronic immunoinflammatory disorders (CIIDs), e.g., autoimmune and autoinflammatory diseases. Bonnie and Ellen were happy to finally interview digital
The emergence of post-COVID syndrome shines new light on the old problem of post-viral syndromes In Part 1, we discussed how the rise of long covid shines new light on chronic post-viral disorders long ignored by researchers and clinicians. But this issue didn’t just appear with the SARS-COV-2 COVID-19 pandemic.